Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Earlens® Contact Hearing Solution has received FDA clearance and commercial launch. Clinical studies show it provides superior sound quality and speech understanding in noisy environments compared to conventional hearing aids. It delivers the broadest bandwidth available among hearing aids by directly vibrating the eardrum using a custom-fitted lens placed on the tympanic membrane[2][3][5].
"Clinical studies have shown that extended bandwidth hearing can make it easier for people with mild to severe hearing impairment understand speech in noisy environments, and that the Earlens system provides a superior sound quality experience."[5]
Named one of Time magazine’s Best Inventions of 2020[3].
No traditional clinical trial pipeline as with therapeutics; product iterations are cleared via regulatory pathways.
Second-generation device received FDA clearance in 2019[2][3].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Earlens.